IL167472A - Use of halogen anesthetic formulated to formulate for use in treating patients undergoing ischemic event - Google Patents
Use of halogen anesthetic formulated to formulate for use in treating patients undergoing ischemic eventInfo
- Publication number
- IL167472A IL167472A IL167472A IL16747205A IL167472A IL 167472 A IL167472 A IL 167472A IL 167472 A IL167472 A IL 167472A IL 16747205 A IL16747205 A IL 16747205A IL 167472 A IL167472 A IL 167472A
- Authority
- IL
- Israel
- Prior art keywords
- formulation
- tissue
- ischemic event
- anesthetic
- patient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 91
- 238000009472 formulation Methods 0.000 title claims abstract description 87
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 47
- 239000003983 inhalation anesthetic agent Substances 0.000 title claims abstract description 21
- 238000011282 treatment Methods 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 6
- 230000002107 myocardial effect Effects 0.000 claims abstract description 14
- 230000001537 neural effect Effects 0.000 claims abstract description 7
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims description 42
- 229960002725 isoflurane Drugs 0.000 claims description 41
- DPYMFVXJLLWWEU-UHFFFAOYSA-N desflurane Chemical compound FC(F)OC(F)C(F)(F)F DPYMFVXJLLWWEU-UHFFFAOYSA-N 0.000 claims description 39
- 229960003537 desflurane Drugs 0.000 claims description 36
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 claims description 27
- DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 claims description 26
- 229960000305 enflurane Drugs 0.000 claims description 25
- 229960002078 sevoflurane Drugs 0.000 claims description 25
- 238000001990 intravenous administration Methods 0.000 claims description 23
- 238000001802 infusion Methods 0.000 claims description 20
- 208000006011 Stroke Diseases 0.000 claims description 13
- 208000010125 myocardial infarction Diseases 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000004945 emulsification Methods 0.000 claims description 12
- 230000002490 cerebral effect Effects 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 229960003132 halothane Drugs 0.000 claims description 8
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 208000007474 aortic aneurysm Diseases 0.000 claims description 5
- 210000002216 heart Anatomy 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 230000008439 repair process Effects 0.000 claims description 5
- 238000002583 angiography Methods 0.000 claims description 4
- 238000002399 angioplasty Methods 0.000 claims description 4
- 230000000747 cardiac effect Effects 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 4
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 208000004221 Multiple Trauma Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 210000001508 eye Anatomy 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000027032 Renal vascular disease Diseases 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 238000013172 carotid endarterectomy Methods 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 208000015670 renal artery disease Diseases 0.000 claims description 2
- 210000005166 vasculature Anatomy 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 44
- 210000001519 tissue Anatomy 0.000 description 43
- 239000000839 emulsion Substances 0.000 description 35
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 239000003981 vehicle Substances 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 230000004224 protection Effects 0.000 description 17
- 239000003193 general anesthetic agent Substances 0.000 description 16
- 230000003444 anaesthetic effect Effects 0.000 description 14
- 230000005961 cardioprotection Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229940035674 anesthetics Drugs 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 206010061216 Infarction Diseases 0.000 description 11
- 230000007574 infarction Effects 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 239000008346 aqueous phase Substances 0.000 description 9
- 206010002091 Anaesthesia Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000037005 anaesthesia Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 206010039897 Sedation Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 235000010445 lecithin Nutrition 0.000 description 7
- 239000000787 lecithin Substances 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 230000036280 sedation Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 230000004112 neuroprotection Effects 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 206010011086 Coronary artery occlusion Diseases 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000004 hemodynamic effect Effects 0.000 description 5
- 230000002669 organ and tissue protective effect Effects 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004868 gas analysis Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000001778 Coronary Occlusion Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229960002455 methoxyflurane Drugs 0.000 description 2
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 208000007257 Budd-Chiari syndrome Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019713 Hepatic vein thrombosis Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 206010054880 Vascular insufficiency Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000036757 core body temperature Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- -1 glycerol Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000054999 human core Human genes 0.000 description 1
- 108700026469 human core Proteins 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003975 mesenteric artery Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229950011087 perflunafene Drugs 0.000 description 1
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000006200 vaporizer Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000023577 vascular insufficiency disease Diseases 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41793402P | 2002-10-11 | 2002-10-11 | |
| PCT/US2003/031826 WO2004032858A2 (en) | 2002-10-11 | 2003-10-09 | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL167472A true IL167472A (en) | 2013-10-31 |
Family
ID=32094122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL167472A IL167472A (en) | 2002-10-11 | 2005-03-16 | Use of halogen anesthetic formulated to formulate for use in treating patients undergoing ischemic event |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7999011B2 (enExample) |
| EP (1) | EP1558226B1 (enExample) |
| JP (1) | JP5210486B2 (enExample) |
| KR (2) | KR101403264B1 (enExample) |
| CN (2) | CN1703209A (enExample) |
| AT (1) | ATE546136T1 (enExample) |
| AU (1) | AU2003282464B2 (enExample) |
| BR (1) | BR0314617A (enExample) |
| CA (1) | CA2500310C (enExample) |
| DK (1) | DK1558226T3 (enExample) |
| ES (1) | ES2382911T3 (enExample) |
| HK (1) | HK1079703A1 (enExample) |
| IL (1) | IL167472A (enExample) |
| MX (1) | MXPA05003741A (enExample) |
| NZ (1) | NZ539298A (enExample) |
| PL (1) | PL219493B1 (enExample) |
| RU (1) | RU2350323C2 (enExample) |
| WO (1) | WO2004032858A2 (enExample) |
| ZA (1) | ZA200502741B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003026611A2 (en) | 2001-09-26 | 2003-04-03 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US7449616B2 (en) | 2002-12-24 | 2008-11-11 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| ES2573253T3 (es) * | 2006-09-20 | 2016-06-06 | The Board Of Regents Of The University Of Texas System | Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor |
| GB0619499D0 (en) | 2006-10-03 | 2006-11-08 | Lucent Technologies Inc | Encrypted data in a wireless telecommunications system |
| DE112008002914A5 (de) * | 2007-11-06 | 2010-09-30 | B. Braun Melsungen Ag | Einen hydrophoben Wirkstoff enthaltende wässrige Emulsionen |
| CN107661293A (zh) * | 2008-01-22 | 2018-02-06 | 得克萨斯大学体系董事会 | 用于局部麻醉和/或疼痛缓解的含有萃取溶剂的挥发性麻醉剂组合物 |
| AU2015200210B2 (en) * | 2008-01-22 | 2016-08-11 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| US20110159078A1 (en) * | 2008-01-22 | 2011-06-30 | Vapogenix, Inc | Volatile Anesthetic Compositions and Methods of Use |
| AU2010245932B2 (en) * | 2009-05-05 | 2015-08-06 | Board Of Regents, The University Of Texas System | Novel formulations of volatile anesthetics and methods of use for reducing inflammation |
| RU2408396C1 (ru) * | 2009-07-30 | 2011-01-10 | Государственное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия Федерального агентства по здравоохранению и федеральному развитию" | Комбинированная двухсегментарная регионарная анестезия при выполнении каротидной эндартерэктомии у больных критической ишемией нижних конечностей и выраженным болевым синдромом |
| US20120219596A1 (en) | 2009-07-30 | 2012-08-30 | Wendelin Stark | Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event |
| FR2956323B1 (fr) * | 2010-02-15 | 2013-12-20 | Air Liquide | Medicament gazeux inhalable a base d'argon contre les deficiences ou defaillances d'organes peripheriques |
| JP2014520157A (ja) | 2011-06-24 | 2014-08-21 | ベイポジェニックス インコーポレイテッド | 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法 |
| EP3854389A1 (en) * | 2013-03-15 | 2021-07-28 | Vapogenix, Inc. | Novel analgesic compositions |
| ITMO20130075A1 (it) * | 2013-03-22 | 2014-09-23 | Enrico Giuliani | Dispositivo di somministrazione |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1018773A (en) * | 1962-09-13 | 1966-02-02 | Bellon Labor Sa Roger | ª‡-phenyl-ª‰-2-furyl-propionitrile derivatives |
| US4073943A (en) | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
| US5628930A (en) | 1992-10-27 | 1997-05-13 | Alliance Pharmaceutical Corp. | Stabilization of fluorocarbon emulsions |
| US5635538A (en) | 1993-03-16 | 1997-06-03 | Alliance Pharmaceutical Corp. | Fluorocarbon emulsions with reduced pulmonary gas-trapping properties |
| JP2961034B2 (ja) * | 1993-09-16 | 1999-10-12 | アルプス電気株式会社 | 磁気ヘッド |
| DE69429524T2 (de) | 1993-09-24 | 2002-08-08 | The University Of British Columbia, Vancouver | Aminocyclohexylester und ihre anwendung |
| FR2726267B1 (fr) * | 1994-10-26 | 1998-01-02 | Smithkline Beecham Lab | Nouveaux agents anti-arythmiques, compositions pharmaceutiques les contenant, et procede pour les preparer |
| GB2350297A (en) * | 1999-05-27 | 2000-11-29 | Abbott Lab | Injectable halogenated anesthetic formulation in emulsion form |
| CA2416535C (en) * | 2000-07-26 | 2010-11-16 | Taro Pharmaceutical Industries Ltd. | Non-sedating barbiturate compounds as neuroprotective agents |
-
2003
- 2003-10-09 HK HK05112083.8A patent/HK1079703A1/zh unknown
- 2003-10-09 MX MXPA05003741A patent/MXPA05003741A/es active IP Right Grant
- 2003-10-09 BR BR0314617-0A patent/BR0314617A/pt not_active Application Discontinuation
- 2003-10-09 AU AU2003282464A patent/AU2003282464B2/en not_active Ceased
- 2003-10-09 JP JP2004543499A patent/JP5210486B2/ja not_active Expired - Lifetime
- 2003-10-09 ES ES03774657T patent/ES2382911T3/es not_active Expired - Lifetime
- 2003-10-09 EP EP03774657A patent/EP1558226B1/en not_active Expired - Lifetime
- 2003-10-09 AT AT03774657T patent/ATE546136T1/de active
- 2003-10-09 WO PCT/US2003/031826 patent/WO2004032858A2/en not_active Ceased
- 2003-10-09 NZ NZ539298A patent/NZ539298A/en not_active IP Right Cessation
- 2003-10-09 DK DK03774657.5T patent/DK1558226T3/da active
- 2003-10-09 US US10/682,303 patent/US7999011B2/en active Active
- 2003-10-09 KR KR1020057006049A patent/KR101403264B1/ko not_active Expired - Fee Related
- 2003-10-09 CN CNA2003801012256A patent/CN1703209A/zh active Pending
- 2003-10-09 CA CA2500310A patent/CA2500310C/en not_active Expired - Fee Related
- 2003-10-09 PL PL376217A patent/PL219493B1/pl unknown
- 2003-10-09 KR KR1020127005009A patent/KR20120030598A/ko not_active Ceased
- 2003-10-09 CN CN2011101820964A patent/CN102283821A/zh active Pending
- 2003-10-09 RU RU2005114008/14A patent/RU2350323C2/ru not_active IP Right Cessation
-
2005
- 2005-03-16 IL IL167472A patent/IL167472A/en active IP Right Grant
- 2005-04-05 ZA ZA200502741A patent/ZA200502741B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003282464B2 (en) | 2010-02-25 |
| PL219493B1 (pl) | 2015-05-29 |
| CA2500310A1 (en) | 2004-04-22 |
| AU2003282464A1 (en) | 2004-05-04 |
| HK1079703A1 (zh) | 2006-04-13 |
| ATE546136T1 (de) | 2012-03-15 |
| RU2005114008A (ru) | 2005-10-27 |
| US20040127578A1 (en) | 2004-07-01 |
| NZ539298A (en) | 2008-11-28 |
| KR20050056230A (ko) | 2005-06-14 |
| WO2004032858A3 (en) | 2004-09-23 |
| EP1558226A4 (en) | 2008-04-02 |
| KR20120030598A (ko) | 2012-03-28 |
| KR101403264B1 (ko) | 2014-06-02 |
| CN1703209A (zh) | 2005-11-30 |
| CA2500310C (en) | 2013-03-12 |
| US7999011B2 (en) | 2011-08-16 |
| JP5210486B2 (ja) | 2013-06-12 |
| ES2382911T3 (es) | 2012-06-14 |
| RU2350323C2 (ru) | 2009-03-27 |
| DK1558226T3 (da) | 2012-05-07 |
| EP1558226A2 (en) | 2005-08-03 |
| ZA200502741B (en) | 2006-02-22 |
| EP1558226B1 (en) | 2012-02-22 |
| CN102283821A (zh) | 2011-12-21 |
| BR0314617A (pt) | 2005-08-02 |
| MXPA05003741A (es) | 2005-06-17 |
| JP2006504740A (ja) | 2006-02-09 |
| PL376217A1 (en) | 2005-12-27 |
| WO2004032858A2 (en) | 2004-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0966291B1 (en) | Medicinal preparation containing a lipophilic inert gas | |
| US7999011B2 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
| CA2217742A1 (en) | Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal | |
| JP5684954B1 (ja) | 安定性を改善したロクロニウム製剤 | |
| JP2006504740A5 (enExample) | ||
| JP2011102290A (ja) | 人工心肺に関連する神経障害を制御するためのキセノンの使用 | |
| Natalini et al. | Intravenous 15% isoflurane lipid nanoemulsion for general anesthesia in dogs | |
| WO2018195292A1 (en) | Ketamine and propofol admixture | |
| JP7752425B2 (ja) | ２，２，６，６－テトラメチル－１－ピペリジニルオキシルの揮発使用による細胞死抑制と組織保護 | |
| CN121175044A (zh) | 含有依托咪酯衍生物与丙泊酚的药物组合及其用途 | |
| CN120769745A (zh) | 含有依托咪酯衍生物与环泊酚的药物组合及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |